Notícias e Atividades da Intellia Therapeutics

Intellia Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Intellia Therapeutics é uma empresa listada sob o símbolo NTLA (US).

Veja o organograma con seus 22 executivos principais

Biografias mais buscadas da Intellia Therapeutics

• John Leonard, President, Chief Executive Officer and Director
• Bill Chase, Director
• Jesse Goodman, Director

Recentes movimentos de executivos em Intellia Therapeutics

• Laura Sepp-Lorenzino, Executive Vice President and Chief Scientific Officer, deixou a Companhia  (Notícia publicada em 10 de janeiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Intellia Therapeutics.

Intellia Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Intellia Therapeutics

• Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics
• Press Releases - Intellia Therapeutics
• Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates - Intellia Therapeutics
• Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose - Intellia Therapeutic
• Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022 - Intellia Therapeutics
• Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics
• Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors - Intellia Therapeutics
• Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference - Intellia Therapeutics
• Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) | Intellia Therapeutics
• Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology | Intellia Therapeutics
• View more press releases Close

Redes sociais sobre Intellia Therapeutics

• Intellia Therapeutics na Wikipedia, Google News e Yahoo Finance
• Intellia Therapeutics na LinkedIn, Twitter e YouTube